U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class
Concept
Record UNII
6D53G0FD0Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PLASMA PROTEIN FRACTION (HUMAN)
WHO-DD  
Common Name English
PLASMA PROTEIN FRACTION HUMAN
Common Name English
PLASMA PROTEIN FRACTION,HUMAN [VANDF]
Common Name English
PLASMA, PROTEIN FRACTION (HUMAN)
Common Name English
PLASMA PROTEIN FRACTION (HUMAN) [WHO-DD]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 640.93
Created by admin on Mon Oct 21 19:43:59 UTC 2019 , Edited by admin on Mon Oct 21 19:43:59 UTC 2019
CFR 21 CFR 640.92
Created by admin on Mon Oct 21 19:43:59 UTC 2019 , Edited by admin on Mon Oct 21 19:43:59 UTC 2019
CFR 21 CFR 640.91
Created by admin on Mon Oct 21 19:43:59 UTC 2019 , Edited by admin on Mon Oct 21 19:43:59 UTC 2019
CFR 21 CFR 640.90
Created by admin on Mon Oct 21 19:43:59 UTC 2019 , Edited by admin on Mon Oct 21 19:43:59 UTC 2019
CFR 21 CFR 640.94
Created by admin on Mon Oct 21 19:43:59 UTC 2019 , Edited by admin on Mon Oct 21 19:43:59 UTC 2019
Code System Code Type Description
RXCUI
33835
Created by admin on Mon Oct 21 19:43:59 UTC 2019 , Edited by admin on Mon Oct 21 19:43:59 UTC 2019
PRIMARY RxNorm
EVMPD
SUB127871
Created by admin on Mon Oct 21 19:43:59 UTC 2019 , Edited by admin on Mon Oct 21 19:43:59 UTC 2019
PRIMARY
This is a non-substance concept
Related Record Type Details
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
GLE is approximately 97.5% bound to human plasma proteins independent of concentration from 0.1 to 30 ?M (800 to 25,200 ng/mL).
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro, human plasma protein binding was determined to be low (<18%) across a range of peramivir concentrations (10-1000 ng/mL) with no partitioning into red blood cells (Study DM99362).
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Glasdegib is 91% bound to human plasma proteins in vitro
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The percentages ixabepilone bound to proteins at concentrations of 50, 500 and 5000 ng/mL were 76.6%, 72.0% and 67.1%, respectively. The protein binding of ixabepilone was not concentration dependent from 50 ng/mL to 5000 ng/mL.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
primarily to alpha-1-acid glycoprotein.
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding is independent on nelarabine concentrations.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
For M16, protein binding was moderate and ranged from 82.6 to 85.7% 0.5 hr after avanafil administration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding was greater than 99% and is independent of plasma concentrations.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LDV is >99.8% bound to human plasma proteins when determined in vitro with equilibrium dialysis. In agreement with in vitro data, LDV protein binding was ‰ 98% in healthy subjects and in subjects with renal or hepatic impairment.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
Encorafenib is 86% bound to human plasma proteins and binding is not concentrationdependent
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
The in vitro protein binding in human plasma is below 8% for tipiracil.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
~90% Gilteritinib bound to plasma proteins, mainly albumin
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro, protein binding of lorlatinib to human plasma proteins, including serum albumin and ?1-acid glycoprotein, was 66% at a concentration of 2.4 ?M.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
BINDER->LIGAND
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding of alvimopan was independent of concentration over ranges observed clinically and averaged 80% .
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
BINDER->LIGAND
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The protein binding of M1 is ~97% and is concentration independent.
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The plasma protein binding of milnacipran is approximately 13% and is independent of the concentration (Study# M013).
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The protein binding is concentration dependent and decreases with increasing telaprevir concentrations at all concentrations of human serum albumin (HSA) and ?-1-acid glycoprotein (AAG). In addition, protein binding of telaprevir is affected by the concentration of HSA and AAG.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 ?g/mL).
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In human plasma, the binding of R093877 increased at higher pH values. In the pH-range 7.1 to 7.7, the percentage bound increased from 23.3% to 35.5%
BINDING
LIGAND->BINDER
BINDING
PARENT -> BIOSIMILAR
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
decreases as concentration increases
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro, protein binding of talazoparib is 74% and is independent of talazoparib concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
Binding of crizotinib to human plasma proteins in vitro is 91% and is independent of drug concentration.
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding of omadacycline is approximately 20% and is not concentration dependent.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The in vitro protein binding in human plasma is greater than 96 % for trifluridine.
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
Protein binding of eravacycline to human plasma proteins increases with increasing plasma concentrations, with 79% to 90% (bound) at plasma concentrations ranging from 100 to 10,000 ng/mL.
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Etelcalcetide is primarily bound to plasma albumin and the plasma non-covalent protein binding is less than 50%.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding increased as ara-G concentrations increased.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The percentage of [14C]temsirolimus bound to proteins at concentrations of 10 ng/mL when calculated for undiluted human plasma in erythrocyte suspensions was 85.0%
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDER->LIGAND
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
When detennined in human plasma samples following a single dose of micafungin I00 mg, micafungin binding to plasma protein were approximately 99.8%. Micafungin protein binding in
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro, protein binding of alpelisib is 89% and is independent of concentration.
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
An in vitro study demonstrated that sarecycline was 62.5% to 74.7% bound to human plasma proteins at tested sarecycline concentrations of 0.5 ?g/mL to 50 ?g/mL.
Related Record Type Details
ACTIVE MOIETY
This is a non-substance concept